Paulino Arnold C
Department of Radiation Oncology, The University of Iowa College of Medicine, Iowa City, Iowa, USA.
Pediatr Hematol Oncol. 2003 Mar;20(2):111-7. doi: 10.1080/0880010390158702.
Limited information is available regarding the efficacy of external beam radiation therapy in the palliation of metastatic disease from neuroblastoma. From 1960 to 2000, 29 children with 53 metastatic sites received palliative radiotherapy. There were 26 soft tissue (group I), 19 bone (group II), 5 brain (group III), and 3 hepatic (group IV) treated sites. Median radiotherapy doses for groups I, II, III, and IV sites were 2000, 2000, 2400, and 450 cGy, respectively. For group I sites, complete response was complete disappearance of mass, partial response was > or =50% resolution of mass, no response was <50% resolution or < or =25% progression of mass, and progressive disease was >25% progression of mass. For group II sites, complete response was complete pain relief without medication, partial response was > or =50% pain relief with or without medication, no response was <50% change in pain with medication, and progressive disease was increase in pain and/or medication. Median survival was 2.5 months after palliative radiotherapy. For group I sites, complete response was seen in 1 (4%) while partial response was documented in 19 (73%). Duration of response was until death in 18 responders (90%); 2 patients relapsed with an increasing soft tissue mass at 5 months and 1 year after palliative radiotherapy. For group II sites, complete response was seen in 8 (42%) while partial response was documented in 7 (37%). Duration of response was until death in 14 responders (93%); 1 patient had relapse of pain 1 year after palliative radiotherapy. For the 5 group III children, the median survival was 2.5 months with a range of 2 days to 13 months. Four children had neurological improvement after cranial radiotherapy; one patient progressed and died secondary to neurological compromise 2 days after radiotherapy. For the 3 group IV sites, 2 had improvement in respiratory status after radiotherapy, whereas 1 progressed despite doxorubicin, cyclophosphamide, and radiation. The only patient who survived had a stage IV-S neuroblastoma with liver metastases and is alive 13 years after hepatic irradiation. Radiotherapy is an effective treatment for palliation of symptomatic metastatic disease in children with neuroblastoma.
关于外照射放射治疗在缓解神经母细胞瘤转移性疾病方面的疗效,目前可用信息有限。1960年至2000年期间,29名患有53个转移部位的儿童接受了姑息性放疗。治疗部位包括26个软组织部位(I组)、19个骨部位(II组)、5个脑部位(III组)和3个肝部位(IV组)。I组、II组、III组和IV组部位的中位放疗剂量分别为2000、2000、2400和450 cGy。对于I组部位,完全缓解定义为肿块完全消失,部分缓解定义为肿块消退≥50%,无缓解定义为肿块消退<50%或进展≤25%,疾病进展定义为肿块进展>25%。对于II组部位,完全缓解定义为无需药物即可完全缓解疼痛,部分缓解定义为使用或不使用药物疼痛缓解≥50%,无缓解定义为使用药物后疼痛变化<50%,疾病进展定义为疼痛和/或药物使用增加。姑息性放疗后的中位生存期为2.5个月。对于I组部位,1例(4%)出现完全缓解,19例(73%)记录为部分缓解。18例缓解者(90%)的缓解持续至死亡;2例患者在姑息性放疗后5个月和1年出现软组织肿块增大复发。对于II组部位,8例(42%)出现完全缓解,7例(37%)记录为部分缓解。14例缓解者(93%)的缓解持续至死亡;1例患者在姑息性放疗后1年出现疼痛复发。对于III组的5名儿童,中位生存期为2.5个月,范围为2天至13个月。4名儿童在颅脑放疗后神经功能改善;1例患者在放疗后2天因神经功能损害进展并死亡。对于IV组的3个部位,2例放疗后呼吸状况改善,而1例尽管接受了阿霉素、环磷酰胺和放疗仍进展。唯一存活的患者患有IV-S期神经母细胞瘤伴肝转移,肝脏放疗后13年仍存活。放疗是缓解神经母细胞瘤患儿有症状转移性疾病的有效治疗方法。